

## Strategic Advisory Board

**A Board of accomplished senior experts in pharmaceutical R&D, Health & Life Sciences, Gene Therapy and Branding to give strategic, innovative & accurate advices for the development of FlashCell, especially for business development, licensing strategy, global brand strategy, regulatory affairs and therapeutic & (pre) clinical developments.**

---

### **Pascale Bouillé Ph.D – CEO of Vectalys**

Initially involved in fundamental research in retrovirology, Pascale Bouillé has worked in a number of government and biotechnology research laboratories before creating Vectalys in 2005. From her early days as a PhD student for the Gustave Roussy Institute (Professor Claude Paoletti) and postdoctoral researcher for the Pasteur Institute (Professor Luc Montagnier), she built up over 15 years' experience in R&D projects in the fields of drug discovery and virology. Pascale Bouillé then participated in various programs, first, by conducting gene therapy trials for the Genethon laboratories with Dr Olivier Danos, then followed by the successful transition of viral vector tools from a technology-based to a commercially oriented product with Vectalys. With all the Vectalys' team and tomorrow within FlashCell, she provides a strong scientific background and a high level of specialist expertise and technical support to scientists and project leaders worldwide.

---

### **Nicolas Ferry Ph.D – Regulatory affairs**

Graduated from Paris University where he received a Ph D in 1985 and a M.D. in 1990., Nicolas served as a scientist at the French National Institute for Health Science (INSERM) for more than 25 years. He focused his interest in liver research (creation of its own INSERM lab in Nantes in 2009) and contributed to clinical trials of cell based therapy for liver diseases. Following a role of gene therapy expert for the French regulatory authority, he joined the agency as head of the department of vaccines, blood derived products and advanced therapies. Nicolas is now senior advisor at the cell therapy department of Saint Louis Hospital in Paris and works as a private consultant in the field of ATMPs. Nicolas Ferry co-authored more than 100 scientific publications.

---

### **Jean-Marc Herbert Ph.D – Therapeutic & clinical developments**

Jean-Marc Herbert received an Engineer Degree in Biochemistry and a Ph.D. in cellular and molecular biology from the University of Clermont-Ferrand, France. He has more than 30 years of industrial experience in pharmaceutical R&D. During 10 years, he worked as International Director of the Cardiovascular/thrombosis Research Department for Sanofi R&D. He was Senior VP, in charge of Discovery at Sanofi-Aventis Research, the interim Head of the Anti-infectious Unit and Head of the Early-to-Candidate (E2C) department at Sanofi. He played key roles in the discovery of more than 20 compounds including Plavix® and Arixtra®, and actively contributed to the discovery and development of more than 70 other. He has authored more than 400 papers and is listed as an inventor in more than 50 patents in various fields, including thrombosis, vascular biology, inflammation, cardiology and cancer. Since January 2016, J-M Herbert is the President of Arkely-Consulting, a translational research consulting firm focused on helping biomedical science-based organizations to solve complex challenges associated with modern drug discovery and development. Since January 2017, he acts as a Venture partner for Go Capital, one of the biggest investment funds in France.

---

## **Jean-Christophe Huertas – Global Brand Strategy & Marketing Communication**

Jean-Christophe Huertas has more than 25 years of experience in Brand & Communications within worldwide companies in global and complex organizations. After 8 years (1991-1999) in media relations at Airbus, Alcatel and Rhône Poulenc (Rhodia), he was given global corporate & public affairs communications responsibilities: Rhodia Senior VP Communications & Executive Committee member (1999-2005) ; Executive VP Communications & Public Affairs of Nestlé France & Executive Committee member; Managing Director, Brand & Communications & Executive Committee member of Newedge (50/50 JV between Société Générale and Crédit Agricole), a leading Company in the world of multi-asset brokerage (2008-2012). Then, he joined in 2013 the international FTI Consulting Strategic Communications practice, as Vice-President leading the corporate communications and media Department. Since 2014, he is the CEO of H2D Advisory, a consulting & advisory firm specialized in Strategy & Communications. JC Huertas obtained a degree in law and is a graduate of the Institut d'Etudes Politiques. He has a post-graduate diploma (DESS) in Defense & International Relations of the University Paris 2 Panthéon-Assas

---

## **Franck Lescure – General partner Bioseeds IV Auriga Partners**

Franck Lescure is in charge of Life Sciences investments at AURIGA Partners. He manages the Fund AURIGA IV *Bioseeds* specialized in Infectiology and Microbiology and is directly involved in commitments of AURIGA Partners Funds in Amoéba (Euronext: AMEBA), Cytoo, EnobraQ, Erytech Pharma (Euronext: ERYP), Fab'entech, Flashcell, Pherecydes, Median Technologies (Alternext: ALMDT), Nosopharm and Pylote. Before Auriga Partners, Franck has been part as a scientist of the five initial years of Genset, one of the first French biotech startups, he has spent several years in the Air Liquide group and has been in charge of several investments as member of the Venture Capital team of Crédit Lyonnais Private Equity which became Omnes Capital. Franck is an alumnus of the Ecole Normale Supérieure and the Institut Pasteur. He holds a PhD in Microbiology and Virology and a MBA from the Collège des Ingénieurs

---

## **Jean-Pierre Saintouil Ph.D – Business Development & Licensing**

With a training in Biochemistry and Business, Jean-Pierre Saintouil has a 35 years experience in the field of Health and Life Sciences. He has been successively responsible for International Sales and Director Marketing at Sanofi and Beckman, Director of Business Unit for Bio-Rad, Director of Technology transfer and Licensing at Pasteur Institute, Director of the Cancer-Bio-Santé Cluster and Director of the health Business Unit of Toulouse-Tech-Transfer.

---

## **Contact FlashCell**

### **FlashCell**

Parc Technologique du Canal - Bâtiment Canal Biotech 2  
3, rue des satellites - 31400 Toulouse – France

Tel: +33(0)5 61 28 70 75

[www.flashcell.fr](http://www.flashcell.fr)

[contact@flashcell.fr](mailto:contact@flashcell.fr)